Lipids and the kidney

Abstract

Part 1 Lipids as a risk factor for renal disease: lipid abnormalities in progressive renal insufficiency hypertension, hyperlipidemia and microalbuminuria apolipoprotein E phenotype and renal disease lipoprotein glomerulopathy and its pathogenesis cholesterol as a predictor of progression in diabetic renal disease cholesterol as a predictor of progression in nondiabetic chronic renal disease role of lipids in chronic renal allograft rejection. Part 2 Treatment of dyslipidemia in patients with renal disease: effect of lipid-lowering therapy on the progression of renal disease in nondiabetic nephrotic patients treatment of hyperlipidemia in patients with non-insulin-dependent diabetes mellitus with progressive nephropathy effect of antiproteinuric treatment on the lipid profile in nondiabetic renal disease the effect of HMG-CoA reductase inhibitors on chronic allograft rejection long-term low-density lipoprotein immunoapheresis in renal disease. Part 3 Mechanisms of lipid-induced renal injury - experimental insights: role of lipids in progressive renal disease - insights from the analbuminemic rat hyperlipidemia and tissue contents of N-sigma-(carboxymethyl)lysine in streptozotocin diabetes effects of lipids on glomerular fibrinolysis in vitro effects of lipoprotein (a) on mesangial cell biology HMG-CoA reductase inhibitor suppression of glomerular cell proliferation in rats with anti-thy-1.1 nephritis the role of oxidatively modified lipoproteins in lipid nephropathy effect of low-density lipoproteins on mesangial cell expression of monocyte chemoattractant peptides. Part 4 New insights into effects of antilipemic therapy: regulation of mesangial cell proliferation by the mevalonate pathway hypercholesterolemia and progressive kidney disease - the role of macrophages and macrophage-derived products central role of the transcription factor nuclear factor-kB in mesangial cell production of chemokines isoprenoids, ras and proliferative glomerular disease.